Selank is a synthetic heptapeptide (7 amino acids) derived from tuftsin — an endogenous tetrapeptide that is a fragment of the IgG immunoglobulin heavy chain. Selank was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and is registered as an anxiolytic and anti-asthenic drug in Russia and Ukraine (under the trade names Selank and Selanc), where it has been prescribed for anxiety disorders for over a decade.

The Tuftsin Connection

Selank began as a modification of tuftsin (Thr-Lys-Pro-Arg, amino acids 289-292 of IgG), which has known immunomodulatory and neurotropic properties. The development team extended the tuftsin sequence with a Pro-Gly-Pro tripeptide at the C-terminal end to dramatically improve metabolic stability in plasma while preserving and enhancing the anxiolytic properties. The result is a compound that combines anxiety reduction, cognitive enhancement, and neuroprotection in a single molecule with an exceptional safety profile.

Anxiolytic Mechanism: GABA and Beyond

Selank reduces anxiety through multiple converging mechanisms — not a single receptor target:

1. GABA-A potentiation: Selank enhances GABAergic transmission at the GABA-A receptor complex without binding the benzodiazepine site. This produces anxiolysis without sedation, cognitive impairment, or dependence — the major liabilities of traditional GABA-A drugs (benzodiazepines, Z-drugs).

2. Serotonin modulation: Selank increases serotonin metabolism in the brain (5-HT uptake and degradation regulation), contributing to mood stabilization. Serotonergic effects develop over days to weeks of consistent use.

3. Enkephalin protection: Selank inhibits enkephalin-degrading enzymes, prolonging the activity of endogenous opioid peptides associated with stress reduction and mood.

4. BDNF upregulation: Selank increases BDNF (Brain-Derived Neurotrophic Factor) expression — the primary neuroplasticity growth factor. BDNF reduction is associated with anxiety, depression, and cognitive decline; Selank's BDNF-enhancing effect contributes to both its anxiolytic and cognitive-enhancing properties.

No Dependence, Tolerance, or Rebound

The most significant advantage of Selank over conventional anxiolytics is its dependence-free mechanism. Because it does not act through the benzodiazepine binding site, Selank: - Does not produce physical dependence or withdrawal syndrome - Does not cause sedation, psychomotor impairment, or memory suppression - Does not produce rebound anxiety on discontinuation - Can be used continuously without tolerance development

Clinical studies with Selank conducted in Russia over 15+ years of approved use have not documented addiction, withdrawal, or abuse potential.

Cognitive Enhancement Properties

Selank improves cognitive function independent of its anxiolytic effects — a combination not seen with conventional anxiolytics (which typically impair cognition): - Enhanced memory consolidation (particularly declarative and working memory) - Improved learning speed and retention - Increased attention and focus capacity - Reduced cognitive fatigue under stress conditions

These effects are attributed to Selank's BDNF upregulation, serotonergic modulation, and enhanced GABAergic inhibition of noise in neural circuits.

Clinical Evidence

Russian clinical trials for anxiolytic drug registration documented: - Significant reduction in anxiety scale scores vs. placebo - Comparable anxiolytic efficacy to phenibut (a common Russian anxiolytic) with substantially better cognitive safety profile - No sedation, no psychomotor impairment - Immune system enhancement (consistent with tuftsin origin — tuftsin is an immunostimulant)